Patents by Inventor Mary Hynes

Mary Hynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SACRO-ILIAC JOINT STABILIZING IMPLANTS AND METHODS OF IMPLANTATION
    Publication number: 20240122724
    Abstract: Sacro-iliac joint stabilizing implants adapted for implanting across a SI joint from a dorsal approach. Methods of, and delivery tools adapted for implanting sacro-iliac joint stabilizing implants across a SI joint from a dorsal approach.
    Type: Application
    Filed: July 21, 2023
    Publication date: April 18, 2024
    Inventors: Mary E. STUART, Paul M. SAND, Bret W. SCHNEIDER, W. Carlton RECKLING, Francois FOLLINI, Scott A. YERBY, Vikas V. PATEL, Jack B. RENTZ, Richard A. HYNES, Babajide OGUNSEINDE, David A. PROVENZANO
  • Anti-neurturin receptor-A antibody compositions comprising cytokines or neurotrophic factors
    Patent number: 7785588
    Abstract: NTNR?, NTNR? extracellular domain (ECD), NTNR? variants, chimeric NTNR? (e.g., NTNR? immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR?-ligands, for example NTN, by providing NTNR? to the cell.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: August 31, 2010
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Neurturin receptor
    Publication number: 20060292114
    Abstract: NTNR?, NTNR? extracellular domain (ECD), NTNR? variants, chimeric NTNR? (e.g., NTNR? immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR?-ligands, for example NTN, by providing NTNR? to the cell.
    Type: Application
    Filed: August 22, 2006
    Publication date: December 28, 2006
    Inventors: Robert Klein, Arnon Rosenthal, Mary Hynes
  • Neurturin receptor
    Patent number: 6777196
    Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: August 17, 2004
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Neurturin receptor
    Publication number: 20030110525
    Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.
    Type: Application
    Filed: February 3, 2003
    Publication date: June 12, 2003
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Neurturin receptor
    Patent number: 6342348
    Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: January 29, 2002
    Assignee: Genetech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes
  • Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
    Patent number: 6277820
    Abstract: The present invention relates to neuronal formation and methods of treating diseases characterized by abnormalities in the activity of dopaminergic (DA) and serotonergic (5HT) neurons. In particular, the invention relates to a method of forming serotonergic neurons in vitro by contacting neuroprogenitor cells to an effective amount of native sequence, variants and functional fragments of FGF-4, FGF-8 and Shh. Additionally, disclosed is a method for forming dopaminergic neurons by contacting neuroprogenitor cells to an effective amount of FGF-8 and Shh. Further described are compositions, cell culture compositions and medical devices which contain sufficient amount of FGF-8, Shh or FGF-8, Shh and FGF-4 to stimulate differentiation into dopaminergic or serotonergic neurons, respectively.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: August 21, 2001
    Assignee: Genentech, Inc.
    Inventors: Arnon Rosenthal, Mary A. Hynes, Weilan Ye
  • Neurturin receptor
    Patent number: 6025157
    Abstract: NTNR.alpha., NTNR.alpha. extracellular domain (ECD), NTNR.alpha. variants, chimeric NTNR.alpha. (e.g., NTNR.alpha. immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR.alpha.-ligands, for example NTN, by providing NTNR.alpha. to the cell.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: February 15, 2000
    Assignee: Genentech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes